Vimentin, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-Vimentin, Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | Vimentin, Human |
| Clone | REAL1008 |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | n/a |
| Format | fluorescein (FITC) conjugate |
| Size | 200 µL |
| Concentration | n/a |
| Applications | MICS (MACSima Imaging Cyclic Staining), Immunohistochemistry, Immunofluorescence |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Vimentin Antibody, anti-human, FITC, REAdye_lease™. Clone REAL1008 is an antibody fragment derived from the full Vimentin antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity. | Clone REAL1008 recognizes the human Vimentin antigen, a 57 kD molecule which is one of the most widely expressed and highly conserved proteins of the type III intermediate filament (IF) protein family. Vimentin is expressed in a wide range of cell types, including pancreatic precursor cells, sertoli cells, neuronal precursor cells, trophoblastic giant cells, fibroblasts, endothelial cells lining blood vessels, renal tubular cells, macrophages, neutrophils, mesangial cells, leukocytes and renal stromal cells. Increased vimentin expression has been reported in various epithelial cancers including prostate cancer, gastrointestinal tumors, CNS tumors, breast cancer, malignant melanoma, lung cancer and other types of cancers. Vimentin's over-expression in cancer correlates well with increased tumor growth, invasion and poor prognosis. Vimentin has gained much importance as a canonical marker of epithelial-mesenchymal transition (EMT), a cellular re-programming process in which the epithelial cells acquire a mesenchymal phenotype that renders the cells to dramatically alter their shape and exhibit increased motility. This EMT is characterized by the expression of vimentin IFs in epithelial cells, which normally express only keratin IFs. Accordingly, during the reverse process of EMT, known as mesenchymal-epithelial transition (MET), the cells start acquiring epithelial phenotype and show a decreased vimentin expression with lower motility rates. | For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675). |
| Immunogen | n/a |
| Other Names | VIM |
| Gene, Accession # | n/a |
| Catalog # | 130-127-022 |
| Price | $365 |
| Order / More Info | Vimentin, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Ferrari, S. et al. (1986) Coding sequence and growth regulation of the human vimentin gene. Mol. Cell. Biol. 6 (11): 3614-3620. | Sommers, C. L. et al. (1989) Vimentin rather than keratin expression in some hormone-independent breast cancer cell lines and in oncogene-transformed mammary epithelial cells. Cancer Res. 49 (15): 4258-4263. | Satelli, A. et al. (2011) Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell. Mol. Life Sci. 68 (18): 3033-3046. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG